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doi:10.1016/j.ejvs.2008.11.018Abstract Objectives: Atherosclerosis is recognised as an inflammatory disease, and new
diagnostic tools are warranted to evaluate plaque inflammatory activity and risk of cardiovas-
cular events. We investigated [18]-fluorodeoxyglucose (FDG) uptake in vulnerable carotid pla-
ques visualised by positron emission tomography (PET). Uptake was correlated to quantitative
gene expression of known markers of inflammation and plaque vulnerability.
Methods: Ten patients with recent transient ischaemic attack and carotid artery stenosis
(>50%) underwent combined FDG-PET and computed tomography angiography (CTA) the day
before carotid endarterectomy. Plaque mRNA expression of the inflammatory cytokine inter-
leukin 18 (IL-18), the macrophage-specific marker CD68 and the two proteinases, Cathepsin
K and matrix metalloproteinase 9 (MMP-9), were quantified using real-time quantitative poly-
merase chain reaction.
Results: Consistent up-regulation of CD68 (3.8-fold 0.9; mean standard error), Cathepsin K
(2.1-fold 0.5), MMP-9 (122-fold 65) and IL-18 (3.4-fold 0.7) were found in the plaques,
compared to reference-artery specimens. The FDG uptake by plaques was strongly correlated
with CD68 gene expression (rZ 0.71, PZ 0.02). Any correlations with Cathepsin K, MMP-9 or
IL-18 gene expression were weaker.
Conclusions: FDG-PET uptake in carotid plaques is correlated to gene expression of CD68 and
other molecular markers of inflammation and vulnerability.
ª 2008 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.545 8082.
.regionh.dk (M. Græbe).
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FDG-PET and Molecular Pathology in Plaques 715The risk of recurrent stroke within 90 days is 15e20% in
patients presenting with symptoms of transient ischaemic
attack (TIA) or minor stroke.1 Those with severe arterial
diseasedthat is, carotid artery atherosclerotic pla-
quesdhave a conceivable higher risk of recurrence, typi-
cally reported to be 35e40%.2e4 Large, randomised trials
conducted in the 1990s documented that carotid endar-
terectomy (CEA) significantly reduced the risk in patients
with at least 50% stenosis of the relevant (ipsilateral)
carotid artery.5,6 Although the risk of recurrent stroke is,
thus, evident in those having symptomatic carotid artery
stenosis, some of the patients with stenosis do not get
a second event; and asymptomatic patients have only
a small benefit of CEA. A better stratifying mechanism for
patients with TIA or minor stroke being at risk of a second
stroke would prove to be a major improvement in patient
selection.
During the last decade, plaque molecular and structural
composition, rather than degree of stenosis, have proved
a far more important trigger of thromboembolic events.7e9
Evidence of inflammatory processes being pivotal in the
development of vulnerability is growing, and several of the
underlying molecular processes leading to plaque rupture
have been elucidated.10,11 Circulating biomarkers are
currently being evaluated as markers of plaque vulnera-
bility to unmask which patients might benefit from
intensified medical treatment and, eventually, endarter-
ectomy.12,13 In addition, several imaging techniques trying
to depict the vulnerable plaque have emerged.14,15 Posi-
tron emission tomography (PET) is one such promising
imaging technology currently under investigation. Using
the glucose analogue radiotracer [18F]2-fluoro-2-deoxy-D-
glucose (FDG), it has been shown in both, animal and
human, studies that atherosclerotic lesions tends to show
a high FDG uptake. It has been shown, that FDG-PET
uptake in arteries shows good correlation to other
known factors of atherosclerosis (e.g., age),16e19 and that
the FDG uptake in carotid plaques in TIA patients corre-
lates well to macrophage quantities within the
plaque.20,21
The aim of the present study was to assess to what
extent FDG-PET reflects key pathological molecular
processes in carotid plaques to permit non-invasive imaging
of these processes. To do so, we combined real-time
quantitative polymerase chain reaction (qPCR) of excised
endarterectomised plaques with preoperative FDG-PET
imaging. We investigated gene expression of the mainly
constitutively expressed macrophage-surface-protein CD68
and of known mediators of vulnerabilitydinterleukin 18
(IL-18),11,22 matrix metalloproteinase 9 (MMP-9)10 and the
cathepsin cysteine proteinase Cathepsin K (CatK), which
degrades collagen.23e25
Methods
Ethics
The study was approved by the Danish National
Committee on Biomedical Research Ethics (Jr. no.:
0120065513), and all participants gave written informed
consent on inclusion.Patients
Ten patients with a carotid artery stenosis of 50% or more,
shown by duplex ultrasound,26 and symptoms of an ipsi-
lateral cerebral event within 3 months prior to operation
were included. The day before carotid endarterectomy, all
patients had an FDG-PET/computed tomography (CT) and
a physical exam, and blood samples were drawn.
FDG-PET/computed tomography angiography (CTA)
After an overnight fast (6 h), a combined PET/CTA (Siemens
Biograph 16, Siemens AG Healthcare Sector, Erlangen,
Germany) was performed over the neck region, 3 h after
intravenous administration of 400 MBq FDG. Two trained
investigators (MG and LB), blinded to molecular data, used
the advanced, open-source PACS station DICOM viewer
OsiriX v. 2.7.5 (http://www.osirix-viewer.com) to place
regions of interest (ROIs) around the common carotid artery
and the internal carotid artery. ROIs placed within the
lumen of the jugular veins were used for blood-pool read-
ings. Mean and maximum standardised uptake values
(SUVmean and SUVmax) were noted, which represent counts
within the region, corrected for patient weight and decay-
corrected injected FDG dose. Alignment of excised plaques
to corresponding transverse image sections was secured by
measurements of bidirectional distance of plaque from the
bifurcation, as noted preoperatively. An average of SUVmax
ROIs corresponding to the excised plaque was divided by an
average of SUVmean in blood-pool, which yields the target-
to-background ratio (TBR).20,21,27,28
Plaque Preparation
Carotid endarterectomy was performed under local
anaesthesia and plaques were removed gently, photo-
graphed and sliced transversely in 3-mm thick slices.
Careful attention was given to orientation and slice origin
(common carotid artery, bifurcation and internal carotid
artery). The slices were immediately conserved in RNA-
Later (Applied Biosystems, CA, USA) and stored at 4 C for
24 h before they were dried and frozen at 80 C until
further analysis. A piece of the superior thyroid artery was
conserved in the same way from all patients, referred to as
the ‘reference’. No visual (macroscopic) pathology was
present in these specimens, but to diminish possible indi-
vidual non-visual pathology revealed in qPCR analysis,
gene-expression analysis from all reference arteries were
pooled in a mathematical manner to ensure a baseline
reference for the entire population.
RNA Extraction and Gene-Expression Analysis
The following molecular analyses on the extracted plaque
slices were done by a team of specialists (SFP and AK)
blinded to the image data.
Samples of 10e35 mg of tissue were dissected from each
slice sample and the TRIzol reagents (Invitrogen Corpo-
ration Carlsbad, CA, USA) were used for total RNA
extraction.
716 M. Græbe et al.The RNA was quantified and assigned RNA-integrity
values using the Agilent 2100 Bioanalyzer (Agilent Tech-
nologies Inc. Santa Clara, CA, USA). Due to partially
degraded RNA, we performed a baseline correction on all
assays; effectively excluding degraded RNA to produce
a measure of intact RNA for subsequent input into the
reverse transcriptase procedure.
Reverse transcriptase polymerase chain reaction (RT-
PCR) was performed using the AffinityScript QPCR cDNA
Synthesis Kit (Stratagene, La Jolla, CA, USA). Samples were
run on a Mastercycler gradient RT-PCR machine (Eppendorf
Hamburg, Germany) and cDNA was stored at 20 C until
quantification analysis.
The quantitative PCR (qPCR) analyses were performed
using the Mx3000P and Mx3005 Real-Time PCR Systems
(Stratagene La Jolla, CA, USA). We used SYBR Green for
optimising primer concentrations and for housekeeping
gene-stability measures, whereas the TaqMan assay was
used for multiplex measurements of genes of interest
(GOIs). Reference-tissue data were pooled for all patients
as a ‘universal’ reference to diminish possible non-macro-
scopic individual pathology in the reference arteries. Initial
sequence data were obtained from the National Center for
Biotechnology Information website, and primer and probe
sets were designed using Beacon Designer 7.0 software
(Premier Biosoft International, Palo Alto, CA, USA). All
primers and probes were purchased from Sigma-Aldrich (St.
Louis, MO, USA) and designed with different reporters and
quenchers at the 50-end and 30-end, respectively, allowing
multiplex analysis as desired.
Two triplex analyses were performed. One with house-
keeping gene combined with CD68 and IL-18 and another
with housekeeping gene combined with MMP-9 and
Cathepsin K.
Statistical Analysis
Average plaque-slice expressions of examined genes are
presented as mean standard error of mean (SEM). Data
were tested for deviation from Gaussian distribution by
using the KolmogoroveSmirnov test. All data, but MMP-9,Table 1 Individual patient data
Patient
#
Gender Age
(years)
Time
(days)a
Glucose
(mmol/l)
HgbA1c
(%)
1 F 81 27 6.20 5.50
2 M 76 33 5.70 6.00
3 M 74 74 7.10 6.50
4 F 77 41 6.00 6.50
5 M 67 22 5.70 5.50
6 F 71 28 7.40 5.90
7 M 54 70 3.80 5.80
8 M 66 51 4.60 5.30
9 M 66 74 4.50 6.00
10 M 78 21 5.90 5.70
All blood samples were drawn before FDG injection after an overnight
a Time: time from last symptom till PET in days.
b Degree of stenosis: carotid artery stenosis determined by duplex
c TBR: target-to-background ratio of PET FDG uptake.passed the test. MMP-9 data were log-transformed to obtain
normal distribution. The P-values of the Kolmogorove
Smirnov tests were: 0.84 (CD68), 0.81 (IL-18), 0.99
(Cathepsin K), 0.93 (log MMP-9) and 0.52 (TBR), in accor-
dance with previous testing of larger test materials also
demonstrating normal distribution of these variables.
A one-sample t-test was used to test for overall increase in
expression, compared to the reference (all set to 1, except
for MMP-9, where we use the fact that log 1Z 0). To test
for correlation between gene overexpression and FDG
uptake, an average of both values were calculated for each
patient to reduce uncertainty of co-registering of image
and plaque slices. Correlation coefficients and P-values
were computed using the Pearson method. Where an
extreme value (outlier) was present, statistical testing was
repeated without this value to test robustness of the
correlations. The P-values are all two-tailed and P< 0.05 is
considered as significant. Statistical analysis and graphing
were done using the software programs SPSS v.16 (SPSS
Inc.) and Prism v.5a (Graphpad Software Inc.), respectively.
Results
Single-patient data, with emphasis on known risk factors of
stroke, are outlined in Table 1. Notably, all patients had
normal low-density lipoprotein (LDL) levels, compared to
American guidelines by NCEP,29 and no correlations
between the shown parameters and plaque TBR were found
(data not shown). All patients received both oral anti-
platelet therapy and cholesterol-lowering drugs (statins) by
the time of the PET scan. All patients were previous
smokers.
Quantitative Gene Expression
Data from all slices (nZ 68), independent of patient origin,
are shown in Fig. 1A. Fig. 1B shows, in the same manner,
distribution of gene expression when slices were averaged
for each of the 10 patients. Real-time qPCR average for
individuals (nZ 10, see Fig. 1B) revealed that CD68 was
overexpressed by 3.78 0.92 (PZ 0.014), IL-18 wasLDL
(mg/dL)
Blood
pressure (mmHg)
Degree of
stenosis (%)b
Plaque
TBRc
101 120/60 75 1.56
66 120/70 55 1.66
93 160/100 85 1.20
104 140/70 75 1.28
101 180/90 60 1.50
143 180/80 80 1.31
46 140/80 65 1.90
89 140/80 70 1.40
77 105/70 70 2.71
107 120/60 95 1.61
fast. No correlation was found between TBR and the tabled data.
flow analysis.
Figure 1 Plaque mRNA expression relative to reference (Z1,
dotted line). (A) Every point represents a slice, 4e9 slices per
patient, 68 slices in all. (B) Average of slices for each patient.
Mean SEM. Note log scale.
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highly overexpressed by an average of 122 65 (PZ 0.001)
whereas Cathepsin K averaged in expression by 2.12 0.46-
fold (PZ 0.039), all in comparison to gene expression in
pooled, reference arterial tissue. Correlates between
expression of CD68 and the other genes are shown in
Table 2.
PET/CT Imaging
Fig. 2 shows examples of FDG uptake in plaques in different
subjects, all with symptomatic right-sided carotid plaques.
Averaging of SUVmax, SUVmean and calculation of TBR,Table 2 Correlation between gene expressions
Correlates (nZ 10) Pearson correlation
coefficient (r)
P-value
(two-sided)
CD68 vs. IL-18 0.80* 0.005
CD68 vs. log MMP-9 0.48* 0.033
CD68 vs. Cathepsin K 0.36 0.312
IL-18 vs. log MMP-9 0.75* 0.012
IL-18 vs. Cathepsin K 0.63 0.052
MMP-9 data were log-transformed to obtain Gaussian distribu-
tion as tested by the KolmogoroveSmirnov test.
*P< 0.05.respectively, on transverse PET/CT image slices corre-
sponding to the extension of the excised plaque was used
for quantification of individual plaque uptake.
Correlation of Gene Expression with FDG
Uptake
Figs. 3 and 4 show correlation plots for each of the four
genes investigated, compared to FDG uptake of the pla-
ques. Using data from all 10 patients, significant correla-
tions were found between TBR and CD68 (rZ 0.71,
PZ 0.02), log MMP-9 (rZ 0.69, PZ 0.04), IL-18 (rZ 0.76,
PZ 0.01) and Cathepsin K (rZ 0.70, PZ 0.02) as shown in
Fig. 3. There was one high TBR ‘outlier’. When this was
excluded, for the remaining nine patients, CD68 correlation
to TBR strengthened (rZ 0.88, PZ 0.002), whereas
correlation coefficients of IL-18 (rZ 0.56, PZ 0.12),
log MMP-9 (rZ 0.62, PZ 0.07) and Cathepsin K weakened
and were no longer significantly correlated to TBR.
Apart from MMP-9, significant correlations were
observed between average plaque SUVmax and gene
expression (CD68: rZ 0.64, PZ 0.04; log MMP-9 rZ 0.45,
PZ 0.22; IL-18 rZ 0.77, PZ 0.01; Cathepsin K: rZ 0.67,
PZ 0.03) as shown in Fig. 4. In contrast, poor correlations
were found between SUVmean and gene expression (CD68:
rZ 0.36, PZ 0.30; log MMP-9 rZ 0.59, PZ 0.07; IL-18
rZ 0.65, PZ 0.04; Cathepsin K: rZ 0.69, PZ 0.03).
Discussion
We found up-regulation of CD68, IL-18, MMP-9 and
Cathepsin K gene expression in endarterectomised carotid
plaques from patients with recent TIA. This is in accordance
with previous studies concerning CD68, IL-18 and MMP-
9,10,11 whereas Cathepsin K gene expression has not previ-
ously been studied in endarterectomised plaques.
CD68 (which is mainly constitutively expressed) is a rec-
ognised marker of macrophages30 and we found that both
TBR and SUVmax were correlated with CD68 gene expres-
sion, whereas SUVmean showed a weaker correlation. This is
in agreement with previous reports about the use of
TBR.20,21,27 Hence, our results suggest that TBR is the
optimal parameter to investigate associations between FDG
uptake and plaque gene expression.
The 3.8-fold overexpression of CD68 observed (Fig. 1) is
most probably due to an increased number of macrophages
in the regions of study. We suspect that the increased
uptake of glucose, as demonstrated with FDG-PET, was
largely due to the abundance of macrophages yielding
a high metabolic rate. Macrophages are thought to be the
major contributor of harmful inflammatory actions in
atherosclerosis. In addition, several cytokines, metal-
loproteinases and cathepsins expressed in macrophages
have been identified as contributors in the development of
atherosclerotic lesions. IL-18 is a cytokine identified as
having a role in the late stages of atherosclerotic lesion
development, when thinning of the extracellular matrix
(ECM) renders plaques prone to rupture.7,11 IL-18 is a known
mediator of MMP-9 activation22 and as plasma IL-18
concentrations are elevated in patients with atheroscle-
rosis, its potential as a biomarker of future cardiovascular
Figure 2 Examples of qualitative assessments of FDG uptake in right-side carotid artery plaques from three patients.
(A) Transverse (and (B) sagittal) slice of same patient with high plaque uptake. (C) Intermediate uptake and (D) no or normal
uptake. Both CTA (left), FDG-PET (right) and fused image (middle) are shown.
Figure 3 Correlation plot of A: CD68, B: IL-18, C: log MMP-9
and D: Cathepsin K vs. FDG uptake (TBR). Dotted line
represents reference (‘normal’ artery gene expression).
Figure 4 Correlation plot of (A) CD68, (B) IL-18, (C) log MMP-9
and (D) Cathepsin K vs. FDG uptake (SUVmax). Dotted line
represents reference.
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720 M. Græbe et al.events has been investigated.31e33 IL-18 was up-regulated
3.2-fold in our study (Fig. 1), but the correlation between
IL-18 and TBR was less robust as significance was lost when
the outlier was excluded.
The degradation of ECM is a pivotal step in the process of
destabilising plaques, that is, making them vulnerable, and
the effect is propagated by the release of ECM degrading
proteolytic enzymes including matrix metalloproteinases
and cathepsins.34,35 MMP-9 expression is induced in acti-
vated macrophages36 and evidence is growing for a key role
for MMP-9 in late steps of plaque remodelling.9,37e39 Levels
of circulating MMP-9 are increased in patients with acute
coronary events40 and our group has shown that baseline
plasma levels are associated with the risk of stroke among
patients with carotid artery plaques.41 The extremely high
levels of MMP-9 expression found in the present study
(w1000-fold up-regulation in single specimens) corroborate
our previous findings. Like IL-18, the correlation between
MMP-9 expression and FDG uptake was less robust than that
for CD68 expression. Recent emphasis on cathepsin
cysteine proteases in plaque development and rupture led
us to include Cathepsin K in our study.10,25,34 In comparison
to other cathepsins, Cathepsin K exhibits collagenolytic
properties, and it is expressed by several of the cell types
involved in plaque remodelling.23,24 Although, overall,
there was a 2.1-fold increase in the expression of Cathepsin
K in endarterectomised carotid plaques, any correlation to
FDG uptake was weak.
A limitation of our study was the low number of patients
enrolled. We were able to clearly link gene expression of
CD68 expression with FDG uptake, but an increased number
of patients may be necessary to confirm possible associa-
tions between FDG uptake and IL-18, MMP-9 and Cathepsin
K. FDG uptake appears to be a promising method for non-
invasive plaque characterisation and, possibly, risk strati-
fication of patients with TIAs: this requires elucidation in
prospective studies.
In conclusion, our study reveals that, in a rather
homogenous population of high-risk patients, a grading of
the overall increase in macrophage gene expression of CD68
in carotid plaques can be visualised non-invasively by
means of FDG-PET.
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